Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,639,276
  • Shares Outstanding, K 577,238
  • Annual Sales, $ 2,264 M
  • Annual Income, $ 858,980 K
  • EBIT $ 1,533 M
  • EBITDA $ 1,552 M
  • 60-Month Beta 0.47
  • Price/Sales 10.01
  • Price/Cash Flow 9.36
  • Price/Book 2.36

Options Overview Details

View History
  • Implied Volatility 59.37% (+5.21%)
  • Historical Volatility 17.25%
  • IV Percentile 96%
  • IV Rank 75.49%
  • IV High 72.50% on 10/14/25
  • IV Low 18.96% on 05/21/25
  • Expected Move (DTE 20) 6.25 (15.93%)
  • Put/Call Vol Ratio 2.04
  • Today's Volume 1,472
  • Volume Avg (30-Day) 322
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 7,270
  • Open Int (30-Day) 19,279
  • Expected Range 32.97 to 45.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.28
  • Number of Estimates 4
  • High Estimate 1.41
  • Low Estimate 0.95
  • Prior Year 1.15
  • Growth Rate Est. (year over year) +11.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.83 +3.67%
on 12/16/25
40.50 -3.16%
on 12/01/25
-0.62 (-1.56%)
since 11/26/25
3-Month
34.79 +12.73%
on 09/29/25
41.24 -4.90%
on 11/06/25
+4.18 (+11.93%)
since 09/26/25
52-Week
25.18 +55.76%
on 12/30/24
41.24 -4.90%
on 11/06/25
+13.82 (+54.41%)
since 12/26/24

Most Recent Stories

More News
3 Healthcare Stocks We’re Skeptical Of

3 Healthcare Stocks We’re Skeptical Of

RPRX : 39.22 (-0.08%)
PGNY : 25.80 (+1.14%)
ANIP : 82.41 (+0.28%)
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an...

RPRX : 39.22 (-0.08%)
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty...

RPRX : 39.22 (-0.08%)
DNLI : 16.87 (-0.71%)
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty...

RPRX : 39.22 (-0.08%)
DNLI : 16.87 (-0.71%)
3 Mid-Cap Stocks That Concern Us

3 Mid-Cap Stocks That Concern Us

RPRX : 39.22 (-0.08%)
FHN : 24.51 (unch)
CHD : 85.39 (-0.08%)
Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: ...

RPRX : 39.22 (-0.08%)
3 Value Stocks with Warning Signs

3 Value Stocks with Warning Signs

ST : 33.58 (-0.18%)
RPRX : 39.22 (-0.08%)
OMC : 80.03 (+0.10%)
3 Low-Volatility Stocks We Find Risky

3 Low-Volatility Stocks We Find Risky

RPRX : 39.22 (-0.08%)
ACT : 40.09 (-0.42%)
CBRL : 25.95 (-1.74%)
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?

RPRX : 39.22 (-0.08%)
Royalty Pharma Reports Third Quarter 2025 Results

Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $703 million Raised full year 2025 guidance: Portfolio Receipts expected...

RPRX : 39.22 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 39.66
2nd Resistance Point 39.55
1st Resistance Point 39.38
Last Price 39.22
1st Support Level 39.10
2nd Support Level 38.99
3rd Support Level 38.82

See More

52-Week High 41.24
Last Price 39.22
Fibonacci 61.8% 35.11
Fibonacci 50% 33.21
Fibonacci 38.2% 31.31
52-Week Low 25.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar